Figure 8 shows some of the highlights from the IL‐18 ligand summary page, including tadekinig α, a peptide ligand that binds to and inhibits the pro‐inflammatory activity of IL‐18 and has US Food and Drug Administration orphan drug designation for the treatment of macrophage activation syndrome. Here, IL18 is linked to macrophage activation syndrome.